The development of CRISPR-mediated systems in the study of Duchenne muscular dystrophy

Cai A, Kong X. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy. Human gene therapy methods 2019;30:71-80.


Duchenne muscular dystrophy (DMD) is a severe type of X-linked recessive degenerative muscle disease, caused by mutations in the dystrophin (DMD) gene on the X chromosome. The DMD gene is complex, consisting of 79 exons, and mutations cause changes in the DMD RNA so that the reading frame is altered, and the muscle-specific isoform of the dystrophin protein is either absent or truncated with variable residual function. The emerging CRISPR-Cas9-mediated genome editing technique is being developed as a potential therapeutic approach to treating DMD, because it can permanently replace the mutated dystrophin gene with the normal gene. Prenatal DNA testing can inform whether the female fetus is a carrier of DMD, and the male fetus has inherited a mutation from his mother (50% chance of both). In this paper, we summarize the present status of current and future treatments for DMD.

search previous next tag category expand menu location phone mail time cart zoom edit close